vs

Side-by-side financial comparison of Chemours Co (CC) and Charles River Laboratories (CRL). Click either name above to swap in a different company.

Chemours Co is the larger business by last-quarter revenue ($1.3B vs $994.2M, roughly 1.3× Charles River Laboratories). Chemours Co runs the higher net margin — -3.5% vs -27.8%, a 24.3% gap on every dollar of revenue. On growth, Charles River Laboratories posted the faster year-over-year revenue change (-0.8% vs -2.1%). Chemours Co produced more free cash flow last quarter ($92.0M vs $58.6M). Over the past eight quarters, Charles River Laboratories's revenue compounded faster (-0.9% CAGR vs -1.2%).

The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

CC vs CRL — Head-to-Head

Bigger by revenue
CC
CC
1.3× larger
CC
$1.3B
$994.2M
CRL
Growing faster (revenue YoY)
CRL
CRL
+1.2% gap
CRL
-0.8%
-2.1%
CC
Higher net margin
CC
CC
24.3% more per $
CC
-3.5%
-27.8%
CRL
More free cash flow
CC
CC
$33.4M more FCF
CC
$92.0M
$58.6M
CRL
Faster 2-yr revenue CAGR
CRL
CRL
Annualised
CRL
-0.9%
-1.2%
CC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CC
CC
CRL
CRL
Revenue
$1.3B
$994.2M
Net Profit
$-47.0M
$-276.6M
Gross Margin
11.7%
Operating Margin
-28.5%
Net Margin
-3.5%
-27.8%
Revenue YoY
-2.1%
-0.8%
Net Profit YoY
-261.5%
-28.9%
EPS (diluted)
$-0.32
$-5.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CC
CC
CRL
CRL
Q4 25
$1.3B
$994.2M
Q3 25
$1.5B
$1.0B
Q2 25
$1.6B
$1.0B
Q1 25
$1.4B
$984.2M
Q4 24
$1.4B
$1.0B
Q3 24
$1.5B
$1.0B
Q2 24
$1.6B
$1.0B
Q1 24
$1.4B
$1.0B
Net Profit
CC
CC
CRL
CRL
Q4 25
$-47.0M
$-276.6M
Q3 25
$46.0M
$54.4M
Q2 25
$-380.0M
$52.3M
Q1 25
$-5.0M
$25.5M
Q4 24
$-13.0M
$-214.5M
Q3 24
$-32.0M
$69.7M
Q2 24
$60.0M
$94.1M
Q1 24
$54.0M
$73.0M
Gross Margin
CC
CC
CRL
CRL
Q4 25
11.7%
Q3 25
15.6%
Q2 25
17.2%
Q1 25
17.3%
Q4 24
19.4%
Q3 24
19.0%
34.6%
Q2 24
19.8%
34.5%
Q1 24
20.9%
34.1%
Operating Margin
CC
CC
CRL
CRL
Q4 25
-28.5%
Q3 25
2.5%
13.3%
Q2 25
-15.4%
9.7%
Q1 25
7.6%
Q4 24
-0.1%
-16.7%
Q3 24
-2.1%
11.6%
Q2 24
4.4%
14.8%
Q1 24
5.1%
12.5%
Net Margin
CC
CC
CRL
CRL
Q4 25
-3.5%
-27.8%
Q3 25
3.1%
5.4%
Q2 25
-23.5%
5.1%
Q1 25
-0.4%
2.6%
Q4 24
-1.0%
-21.4%
Q3 24
-2.1%
6.9%
Q2 24
3.9%
9.2%
Q1 24
4.0%
7.2%
EPS (diluted)
CC
CC
CRL
CRL
Q4 25
$-0.32
$-5.57
Q3 25
$0.31
$1.10
Q2 25
$-2.53
$1.06
Q1 25
$-0.03
$0.50
Q4 24
$-0.07
$-4.17
Q3 24
$-0.22
$1.33
Q2 24
$0.39
$1.74
Q1 24
$0.36
$1.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CC
CC
CRL
CRL
Cash + ST InvestmentsLiquidity on hand
$670.0M
$213.8M
Total DebtLower is stronger
$4.1B
$2.1B
Stockholders' EquityBook value
$250.0M
$3.2B
Total Assets
$7.4B
$7.1B
Debt / EquityLower = less leverage
16.40×
0.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CC
CC
CRL
CRL
Q4 25
$670.0M
$213.8M
Q3 25
$613.0M
$207.1M
Q2 25
$502.0M
$182.8M
Q1 25
$464.0M
$229.4M
Q4 24
$713.0M
$194.6M
Q3 24
$596.0M
$210.2M
Q2 24
$604.0M
$179.2M
Q1 24
$746.0M
$327.0M
Total Debt
CC
CC
CRL
CRL
Q4 25
$4.1B
$2.1B
Q3 25
$4.1B
$2.2B
Q2 25
$4.1B
$2.3B
Q1 25
$4.1B
$2.5B
Q4 24
$4.1B
$2.2B
Q3 24
$4.0B
$2.3B
Q2 24
$4.0B
$2.4B
Q1 24
$4.0B
$2.7B
Stockholders' Equity
CC
CC
CRL
CRL
Q4 25
$250.0M
$3.2B
Q3 25
$274.0M
$3.4B
Q2 25
$228.0M
$3.4B
Q1 25
$566.0M
$3.2B
Q4 24
$571.0M
$3.5B
Q3 24
$643.0M
$3.8B
Q2 24
$714.0M
$3.7B
Q1 24
$753.0M
$3.6B
Total Assets
CC
CC
CRL
CRL
Q4 25
$7.4B
$7.1B
Q3 25
$7.5B
$7.5B
Q2 25
$7.5B
$7.6B
Q1 25
$7.4B
$7.6B
Q4 24
$7.5B
$7.5B
Q3 24
$7.5B
$8.0B
Q2 24
$7.2B
$7.9B
Q1 24
$8.0B
$8.2B
Debt / Equity
CC
CC
CRL
CRL
Q4 25
16.40×
0.68×
Q3 25
14.96×
0.64×
Q2 25
17.99×
0.70×
Q1 25
7.18×
0.79×
Q4 24
7.11×
0.65×
Q3 24
6.20×
0.62×
Q2 24
5.53×
0.65×
Q1 24
5.27×
0.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CC
CC
CRL
CRL
Operating Cash FlowLast quarter
$137.0M
$147.5M
Free Cash FlowOCF − Capex
$92.0M
$58.6M
FCF MarginFCF / Revenue
6.9%
5.9%
Capex IntensityCapex / Revenue
3.4%
8.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$51.0M
$518.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CC
CC
CRL
CRL
Q4 25
$137.0M
$147.5M
Q3 25
$146.0M
$213.8M
Q2 25
$93.0M
$204.6M
Q1 25
$-112.0M
$171.7M
Q4 24
$138.0M
$159.4M
Q3 24
$139.0M
$251.8M
Q2 24
$-620.0M
$193.5M
Q1 24
$-290.0M
$129.9M
Free Cash Flow
CC
CC
CRL
CRL
Q4 25
$92.0M
$58.6M
Q3 25
$105.0M
$178.2M
Q2 25
$50.0M
$169.3M
Q1 25
$-196.0M
$112.4M
Q4 24
$29.0M
$83.7M
Q3 24
$63.0M
$213.1M
Q2 24
$-693.0M
$154.0M
Q1 24
$-392.0M
$50.7M
FCF Margin
CC
CC
CRL
CRL
Q4 25
6.9%
5.9%
Q3 25
7.0%
17.7%
Q2 25
3.1%
16.4%
Q1 25
-14.3%
11.4%
Q4 24
2.1%
8.4%
Q3 24
4.2%
21.1%
Q2 24
-44.6%
15.0%
Q1 24
-28.8%
5.0%
Capex Intensity
CC
CC
CRL
CRL
Q4 25
3.4%
8.9%
Q3 25
2.7%
3.5%
Q2 25
2.7%
3.4%
Q1 25
6.1%
6.0%
Q4 24
8.0%
7.5%
Q3 24
5.0%
3.8%
Q2 24
4.7%
3.8%
Q1 24
7.5%
7.8%
Cash Conversion
CC
CC
CRL
CRL
Q4 25
Q3 25
3.17×
3.93×
Q2 25
3.91×
Q1 25
6.74×
Q4 24
Q3 24
3.61×
Q2 24
-10.33×
2.06×
Q1 24
-5.37×
1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CC
CC

Titanium Technologies$563.0M42%
Thermal And Specialized Solutions$443.0M33%
Advanced Performance Materials$312.0M23%
Other Non-Reportable Segment$12.0M1%

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

Related Comparisons